Welcome to our dedicated page for Radius Recycling news (Ticker: RDUS), a resource for investors and traders seeking the latest updates and insights on Radius Recycling stock.
Radius Recycling, Inc. generated company news around recycled metals processing, nonferrous and ferrous market conditions, finished steel operations, earnings releases, and operating initiatives in metal recovery and recycling services. Coverage also included governance changes and capital-structure matters tied to material agreements and shareholder actions.
In July 2025, Radius Recycling completed a merger and became a wholly owned subsidiary of Toyota Tsusho America, Inc. Subsequent RDUS-related developments center on the company's corporate-status transition, delisting and deregistration steps, and historical public-company disclosures.
Radius Health (Nasdaq: RDUS) will announce its second quarter financial results on August 10, 2020, followed by a conference call at 8:30 a.m. ET. The event will offer insights into the company’s financial performance and future strategies. A replay will be available later the same day. Radius specializes in endocrine therapeutics, with notable products like TYMLOS for osteoporosis, and has a growing pipeline that includes investigational drugs for various conditions.
Radius Health has entered a global licensing agreement with Menarini for elacestrant, an oral selective estrogen receptor degrader, currently in late-stage Phase 3 development for advanced ER+/HER2- breast cancer. This deal includes a $30 million upfront payment and potential up to $320 million in milestone payments, plus tiered royalties on sales. Radius will continue to manage the EMERALD Phase 3 study, which involves about 460 patients. The partnership strengthens Menarini's oncology portfolio and provides Radius with financial flexibility for future initiatives.
Summary not available.